Top Markets
Coin of the day
Hemab Therapeutics Holdings, Inc. Common Stock Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG
Rankning i aktier #21709
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm... Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Aktiekurs
$50.82
Senast synkroniserad: 2026-08-11
Marknadsvärde
$102.09M
Förändring (1 dag)
1.90%
Förändring (1 år)
-
Land
US
Handel Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Kategori

Aktiekurshistorik för Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Högsta slutkurs: $50.63 den 2026-08-01

Lägsta slutkurs: $27.02 den 2026-05-01
Aktiekurshistorik för Hemab Therapeutics Holdings, Inc. Common Stock från 2026 till 2026
Årlig aktiekursutveckling
År Prestanda
Inte tillräckligt med data för de angivna datumen.
Aktiekurs för liknande företag eller konkurrenter
Företag Aktiekurs Förändring 1år% Land
$547.71 38.62%
US
$1.04K 58.06%
NL
$145.75 437.43%
US
$118.70 -15.60%
AU
$770.19 8.98%
CH